Page 215 - Haematologica March 2020

17-gene LSC score: mutations and outcome in AML
Nature. 2017;551(7680):384-388.
16. Metzeler KH, Maharry K, Kohlschmidt J, et al. A stem cell-like gene expression signature associates with inferior outcomes and a dis- tinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia. 2013;27(10):
2023-2031.
17. Grimwade D, Mrózek K. Diagnostic and
prognostic value of cytogenetics in acute myeloid leukemia. Hematol Oncol Clin North Am. 2011;25(6):1135-1161.
18. Eisfeld AK, Kohlschmidt J, Mrózek K, et al. Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia. 2018;32(6): 1338-1348.
19. Eisfeld A-K, Mrózek K, Kohlschmidt J, et al. The mutational oncoprint of recurrent cyto- genetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia. 2017;31(10):2211-2218.
20. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331(14):896-903.
21. Schiffer CA, Davis RB, Schulman P, et al. Intensive post remission therapy of acute myeloid leukemia (AML) with cytoxan/etoposide (CY/VP16) and diaza- quone/mitoxantrone (AZQ/MITO). Blood. 1991;78(suppl):460 (abstract 1829).
22. Moore JO, Dodge RK, Amrein PC, et al. Granulocyte-colony stimulating factor (fil- grastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood. 1997;89(3):780-788.
23. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339(23):1649-1656.
24. Moore JO, George SL, Dodge RK, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood. 2005;105(9):3420-3427.
25. Kolitz JE, George SL, Dodge RK, et al. Dose escalation studies of cytarabine, daunoru- bicin, and etoposide with and without mul- tidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induc- tion results of Cancer and Leukemia Group B study 9621. J Clin Oncol. 2004;22(21): 4290-4301.
26. Marcucci G, Moser B, Blum W, et al. A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 anti- sense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. J Clin Oncol. 2007;25(suppl):360s (abstract 7012).
27. Attar EC, Johnson JL, Amrein PC, et al. Bortezomib added to daunorubicin and
cytarabine during induction therapy and to intermediate-dose cytarabine for consolida- tion in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013;31(7):923-929.
28. Blum W, Sanford BL, Klisovic R, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503). Leukemia. 2017;31(1):34-39.
29. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulat- ing factor after initial chemotherapy for eld- erly patients with primary acute myeloge- nous leukemia. N Engl J Med. 1995;332 (25):1671-1677.
30. Kolitz JE, George SL, Marcucci G, et al. P- glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients under age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010;116(9):1413-1421.
31. Lee EJ, George SL, Caligiuri M, et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of Cancer and Leukemia Group B study 9420. J Clin Oncol. 1999;17(9):2831- 2839.
32. Baer MR, George SL, Caligiuri MA, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B study 9720. J Clin Oncol. 2008;26(30):4934-4939.
33. Uy GL, Mandrekar SJ, Laumann K, et al. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017;1(5):331- 340.
34) Roboz GJ, Mandrekar SJ, Desai P, et al. A randomized trial of 10 days of decitabine alone or with bortezomib in previously untreated older patients with acute myeloid leukemia: CALGB 11002 (Alliance). Blood Adv. 2018;2(24):3608-3617.
35. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quan- tification. Nat Biotechnol. 2016;34(5):525- 527.
36. Mrózek K, Eisfeld A-K, Kohlschmidt J, et al. Complex karyotype in de novo acute myeloid leukemia: typical and atypical sub- types differ molecularly and clinically. Leukemia. 2019;33(7):1620-1634.
37. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol. 2006;24(24):3904-3911.
38. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytoge- netic subtype. Cancer Res. 1998;58(18): 4173-4179.
39. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12):3767-3775.
40. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336.
41. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council Trials. Blood. 2010;116(3):354-365.
42. Lugthart S, Gröschel S, Beverloo HB, et al. Clinical, molecular and prognostic signifi- cance of WHO type inv(3)(q21;q26.2)/t(3;3)(q21;q26.2) and vari- ous other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 2010;28(24):3890- 3898.
43. Fasan A, Eder C, Haferlach C, et al. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA muta- tions and are associated with favorable prognosis. Leukemia. 2013;27(2):482-485.
44. Gaidzik VI, Bullinger L, Schlenk RF, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011;29(10): 1364-1372.
45. Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol. 2012;30(25):3109-3118.
46. Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk sub- group of older patients with primary cytoge- netically normal AML within the ELN favor- able genetic category. Blood. 2011;118(26): 6920-6929.
47. Pratcorona M, Abbas S, Sanders MA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognos- tic value. Haematologica. 2012;97(3):388- 392.
48. Schnittger S, Eder C, Jeromin S, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia. 2013;27(1):82-91.
49. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008;22(8):1539- 1541.
50. Bowen D, Groves MJ, Burnett AK, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia. 2009;23(1):203-206.
haematologica | 2020; 105(3)
729